You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, sing…

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

 

Online download statistics by month:

Online download statistics by month: January 2022 to October 2024

AbstractFullPdf
Jan 2022894907314
Feb 2022734753339
Mar 2022611619315
Apr 2022587616298
May 2022548581279
Jun 202211833120241190
Jul 202253805455547
Aug 202225482583421
Sep 202232433313391
Oct 202217541792372
Nov 202217521758341
Dec 202212571261250
Jan 202312701279313
Feb 202314971501357
Mar 202330663082403
Apr 202312921306340
May 202314411446361
Jun 202311901210300
Jul 202314561461259
Aug 202312791289330
Sep 202311601165283
Oct 202313161320390
Nov 202314061417294
Dec 202311701176268
Jan 2024556560199
Feb 2024634640216
Mar 2024820827269
Apr 2024607610244
May 2024518521184
Jun 2024519529203
Jul 2024617618192
Aug 2024431432215
Sep 2024488495191
Oct 2024570576223
Total544445512211091